| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | GPRC5D | Synonyms | None | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p13.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | G protein-coupled receptor class C group 5 member D | ||||
| GTO ID | GTC3793 |
| Trial ID | NCT06298266 |
| Disease | Multiple Myeloma |
| Altered gene | CD19|GPRC5D |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/GPRC5D CAR T |
| Phase | Early_Phase1 |
| Recruitment status | Not Recruiting |
| Title | Clinical Study to Evaluate the Safety, Tolerability and Initial Efficacy of Anti-GPRC5D-CD19-CAR-T in Patients With Relapsed/Refractory Multiple Myeloma |
| Year | 2024 |
| Country | China |
| Company sponsor | Guangdong Second Provincial General Hospital |
| Other ID(s) | GD2H-XYK-001 |
| Cohort 1 | |||||||||||
|
|||||||||||